Alkermes Investigational Site

Atlanta, Georgia 30342

2 studies enrolling now · 23 studies all time

What they study most

Alcohol Dependence, Alcohol Use Disorder, Bipolar I Disorder, Idiopathic Hypersomnia, Major Depressive Disorder, Multiple Sclerosis, Narcolepsy Type 1, Narcolepsy Type 2, Refractory Major Depressive Disorder, Relapsing Remitting Multiple Sclerosis, Schizophrenia, Schizophreniform Disorder

Studies at this site

• A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia — Recruiting now
• A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) — Recruiting now
• A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201) — Completed
• Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 — Completed
• Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder — Completed
• A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 — Completed
• A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder — Completed
• A Study of ALKS 3831 in Adults With Schizophrenia — Completed
• A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia — Completed
• A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD) — Stopped early
• A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD) — Completed
• A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 — Completed
• A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study) — Completed
• A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD) — Completed
• A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study — Completed
• A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD) — Completed
• A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia — Completed
• A Long-Term Safety Study of ALKS 5461 — Completed
• A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) — Completed
• An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia — Completed
• A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia — Completed
• An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) — Completed
• ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence — Completed